Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

Published:2024-08 Issue: Volume: Page:
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Tannir N.M.^ORCID,Albigès L.,McDermott D.F.,Burotto M.,Choueiri T.K.^ORCID,Hammers H.J.,Barthélémy P.^ORCID,Plimack E.R.,Porta C.,George S.,Donskov F.^ORCID,Atkins M.B.,Gurney H.^ORCID,Kollmannsberger C.K.,Grimm M.-O.^ORCID,Barrios C.,Tomita Y.,Castellano D.,Grünwald V.^ORCID,Rini B.I.^ORCID,Jiang R.^ORCID,Desilva H.,Fedorov V.,Lee C.-W.,Motzer R.J.

Funder

The University of Texas MD Anderson Cancer Center

Memorial Sloan-Kettering Cancer Center

Ono Pharmaceutical Co Ltd

Bristol-Myers Squibb Co

Publisher

Elsevier BV

Reference21 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. EAU guidelines on renal cell carcinoma: 2014 update;Ljungberg;Eur Urol,2015

3. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study;Heng;Lancet Oncol,2013

4. Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review;Lalani;Ther Adv Med Oncol,2022

5. On the shoulders of giants: the evolution of renal cell carcinoma treatment-cytokines, targeted therapy, and immunotherapy;Dutcher;Am Soc Clin Oncol Educ Book,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP